• Atopic dermatitis is the most common type of eczema.

Lausanne, Switzerland – March 8, 2019 –Galderma, Nestlé Skin Health’s medical solutions business, presented the final results from a Phase 2b dose-ranging study of nemolizumab, an investigational therapy in adult patients with moderate-to-severe atopic dermatitis (AD), at the late-breaking session of the 2019 American Academy of Dermatology annual meeting (March 1-5).

Galderma’s first and only product in the U.S. to use proprietary XpresHAn Technology™ for the cheeks

• Restylane^® Refyne™ and Restylane Defyne^™ are the first Optimal Balance Technology (OBT™) hyaluronic acid injectables ever approved and launched in Japan, bringing advanced flexibility and natural movement to the market^1,2 
• This expands Galderma’s Restylane portfolio in Japan to four products, enabling treatment of

Both Studies of Next-Generation Topical Retinoid for Acne on the Face, Chest and Back Met All Primary and Secondary Efficacy Endpoints